Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 4/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29412684 | 0.93 | PTPN1 (0.53) | PTPN1KMT2ACASP3TLR2 | |
| SCHEMBL31560034 | 0.93 | PTPN1 (0.53) | PTPN1KMT2ACASP3TLR2 | |
| SCHEMBL13658468 | 0.91 | KMT2A (0.56) | PTPN1KMT2ACASP3TLR2 | |
| SCHEMBL17826082 | 0.91 | KMT2A (0.56) | PTPN1KMT2ACASP3TLR2 | |
| SCHEMBL29400679 | 0.91 | KMT2A (0.56) | PTPN1KMT2ACASP3TLR2 | |
| SCHEMBL12928621 | 0.91 | KMT2A (0.56) | PTPN1KMT2ACASP3TLR2 | |
| SCHEMBL13296556 | 0.91 | PTPN1 (0.52) | PTPN1KMT2ACASP3TLR2 | |
| SCHEMBL14573312 | 0.91 | PTPN1 (0.52) | PTPN1KMT2ACASP3TLR2 | |
| SCHEMBL17446690 | 0.88 | PTPN1 (0.56) | PTPN1KMT2ACASP3 | |
| SCHEMBL11949183 | 0.87 | CASP3 (0.47) | KMT2ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210778-A1 | NOVEL COMPOUNDS | INVIVOGEN SAS (FR) | 2017-07-27 | — | — | US | disclosed |
| WO-2016008946-A1 | NOVEL COMPOUNDS | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2016-01-21 | — | — | WO | disclosed |
| EP-2975046-A1 | Novel compounds | The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth (IE) | 2016-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210778-A1 | NOVEL COMPOUNDS | F12, C1R, F11 | PTPN1 2412/4885KMT2A 4320/4885CASP3 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.